Aziyo Biologics, Inc. announced that Aziyo co-founder C. Randal (Randy) Mills, Ph.D. has assumed the Chief Executive Officer role on an on-going basis. Dr. Mills, who is internationally recognized for his contributions to the field of regenerative medicine, has served as the Company's interim CEO since June 2022. Randy Mills, Ph.D., co-founder of Aziyo Biologics, is an internationally recognized expert in regenerative medicine who has led pioneering biotechnology organizations that have created more than $1 billion in shareholder value for investors.

As CEO of Osiris Therapeutics, he commercialized five cell-therapy products responsible for $1.5 billion in sales and led the company through an IPO that increased shareholder value 41-fold. Osiris was eventually sold to Smith and Nephew for $660 million. Dr. Mills was also a co-founder and officer of Regeneration Technologies, where he led operations, R&D, regulatory and business development through its IPO, growing annual revenues to $150 million.

Randy's patient first leadership style has also helped transform some of nation's most treasured medical institutions, serving as president of the $3 billion California Institute for Regenerative Medicine and CEO of the National Marrow Donor Program/Be The Match, responsible for the nation's supply of bone marrow for transplant. Dr. Mills has received numerous recognitions, including being named an Ernst & Young Entrepreneur of the Year, listed as one of the World's 50 Most Influential People in Regenerative Medicine, and winner of AATB's Hyatt Memorial Award for Scientific Leadership in Transplantation.